Navigation Links
Rosetta Genomics and Weizmann Institute Scientists Identify Role of,microRNA in Cancer Suppression

Findings Published in Molecular Cell Show Potential of microRNAs as Novel Cancer Drug Targets

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, July 05, 2007 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd , a leading microRNA company, announced today research published in the journal Molecular Cell by scientists from the Weizmann Institute of Science and Rosetta Genomics . The findings suggest the potential for a specific, single microRNA (miR-34a) to be used as a drug candidate in cancer therapy to increase programmed cell-death (apoptosis) in the context of the potent tumor suppressor p53.

p53 has been widely accepted as a powerful tumor inhibitor that can prevent or slow the spread of cancer cells by facilitating apoptosis. In this study, activation of p53 in-vivo in mice as well as in cultured human cells induced the expression of a specific microRNA (miR-34a). Based on the likelihood that miR-34a could itself play a role in cellular apoptosis, researchers introduced miR-34a directly into human cancer cell lines to determine its impact on tumor cell behavior. The results clearly demonstrated that overexpression of miR-34a led to increased cancer cell death as well as promoted other important anti-proliferative activities. The ability of miR-34a to promote apoptosis of cancer cells makes it an attractive candidate tumor suppressor. The data presented in Molecular Cell is also supported by recent studies (Gaur et at., 2007, Welch et al. 2007) showing that miR-34a is under-expressed in central nervous system tumors.

"This is a groundbreaking study shedding light on the critical role microRNAs play in fighting cancer and highlights their potential to act as novel drug targets", noted Dr. Dalia Cohen, Global Head of Research and Development at Rosetta Genomics. "By introducing increased amounts of miR-34a into the cell-lines, Rosetta Genomics researchers and the world class team at Weizmann Institut e have been able to show that the overexpression of this specific microRNA is directly linked to tumor suppression. Moreover, the results suggest the potential that a synthetic miR-34a-like agent could be used as a cancer therapy. We strongly believe this research continues to validate the opportunities for microRNA-based therapeutics."

"Demonstrating how p53 utilizes microRNAs to stop the growth of tumor cells through facilitating apoptosis, sheds much light on this critical cancer fighting pathway," said Prof. Moshe Oren of the Weizmann Institute, Principal Investigator of this study. "MicroRNAs have been shown to be involved in the most important cellular processes including apoptosis, and this study helps us better understand their important role in the tumor suppression mechanism."

About p53 Tumor Suppressor

The p53 protein, also known as tumor protein 53 (TP53), is a transcription factor that functions as a major tumor suppressor in mammals. p53 has been described as "the guardian of the genome" referring to its role in maintaining stability by preventing genome mutation. p53 is activated in response to a variety of stress signals, dictating a variety of biochemical and biological outcomes, ranging from effective repair of minor damage to arresting cell cycle progression and induction of apoptotic cell death. Inactivation of the tumor suppressing function of p53 is one of the most frequent genetic alterations in human cancer, and close to half of all human tumors carry p53 gene mutations within their cells. As a transcription factor, p53 can increase or repress the transcription of many hundreds of protein-encoding genes, and this ability is believed to underlie in great part its tumor suppressor functions.

About microRNAs

MicroRNAs (miRNAs) are a recently discovered, naturally occurring form of RNAi. These small RNAs act as protein regulators and have the potential to form the basis for a new class of diagnostics and therape utics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNA expression levels have been shown to be correlated with various disease states and to hold great potential as diagnostics and prognostic markers

About Rosetta Genomics

Rosetta Genomics is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and infectious diseases. For more information please visit:

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of miRNAs in human physiology and disease and the potential of microRNAs in the development of therapeutics and diagnostic products constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics products, which is unproven and may never lead to marketable products; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of Rosetta's product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed under "Key Information - Risk Factors" in Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.



    Alan Zachary

    T: +1-312-944-6784



    Juliane Snowden

    T: +1-212-213-0006

CONTACT: Contact: Media, Alan Zachary, T: +1-312-944-6784,; Investors, Juliane Snowden, T: +1-212-213-0006,

Ticker Symbol: ( NASDAQ-NMS:ROSG)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference
2. Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke
3. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
4. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
5. Southern Research Institute to Present at the 2007 American Association For Cancer Research Annual Meeting
6. Sarasotas Roskamp Institute Announces Positive Safety Data in Human Clinical Study for Alzheimers Disease
7. Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases
8. Schepens Scientists Identify Key to Integrating Transplanted Nerve Cells Into Injured Tissue
9. Karmanos Physician-Scientists Examine Racial Disparities in Patients with Gynecologic Cancer
10. Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases
11. The Sturdier Sex?: Study by Pittsburgh Scientists Finds Female Stem Cells Work Better
Post Your Comments:
(Date:11/26/2015)... 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ... kidney transplantation is expected to boost the market growth, as ... transplantation. --> 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the German ...
Breaking Medicine Technology:
(Date:11/27/2015)... VVA (PRWEB) , ... November 27, 2015 , ... ... motto of progress through sharing, the 2016 Building Better Radiology Marketing ... The conference will begin on Sunday, March 6, 2016, at Caesars Palace in ...
(Date:11/27/2015)... ... 27, 2015 , ... A simply groundbreaking television series, "Voices in America", which ... into an array of issues that are presently affecting Americans. Dedicated to providing the ... show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... Bangalore, Karnataka (PRWEB) , ... November 27, 2015 ... ... the world, Health-E-minds, an innovative online platform for mental health and wellness consultation, ... KleverKid. , This partnership will bridge the knowledge gap experienced by parents and ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... largest, most successful and prominent nonprofit healthcare organizations in the country. They have ... with various organizations, and helped advance the healthcare industry as a whole through ...
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley from Vintage ... style concert posters. This is one of Joplin's most famous and beautiful concert posters. ... University of Michigan in Ann Arbor. The According to Hawley, "It is hard to ...
Breaking Medicine News(10 mins):